CCL2 and breast carcinoma: In the stratified analyses (Figure 1), rs1024611 in CCL2 was found to increase the susceptibility to breast cancer in the BMI≥24 (kg/m2) subgroup (dominant model: OR=1.44, 95% CI=1.09-1.91; addictive model: OR=1.22, 95% CI=1.01-1.47).